InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled “Global Allogeneic Cell Therapy Manufacturing Market by (Product (Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product), Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)) – Market Outlook and Industry Analysis 2030” According to company’s newest research, the global Allogeneic Cell Therapy Manufacturing Market is worth US$ 869.6 million in 2021 and is predicted to reach US$ 3424.1 million in 2030, with a promising CAGR of 17 % between 2022 and 2030.
Get Demo Sample copy of Allogeneic Cell Therapy Manufacturing Market Report at: https://www.insightaceanalytic.com/request-sample/1194
Cell therapies as personalized medical interventions hold enormous promise for curing diseases with insufficient or no treatment options, regenerating impaired tissues and targeting pathologies for which traditional treatment is ineffective. Clinical and preclinical data on allogeneic cell therapy products are encouraging. Allogeneic cell therapy products have massive potential to address a wide variety of unmet medical needs, and several drug candidates are nearing commercialization. Commercialization and large-scale production of allogeneic cell therapy products necessitate the development of novel technologies for the safe and effective generation of allogeneic cells/cell lines and their fully characterized master/working banks. Additionally, robust upstream and downstream manufacturing processes must be developed and integrated with well-designed manufacturing facilities to produce high-quality, affordable products following current GMP regulations for cell therapy product manufacturing.
The market is being driven by the exponential rise of the innovative therapy landscape. Because of the rising incidence of numerous chronic disorders such as cancer, diabetes, and cardiovascular diseases and increased government support for stem cell therapies, allogeneic cell therapy has rapidly gained traction in recent years. Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement in January 2022 to develop and commercialize up to four engineered natural killer cell and/or T cell program for hematologic malignancies and solid tumors derived from induced pluripotent stem cells. A program for acute myeloid leukaemia and a program for multiple myeloma, both of which could use the iNK or a gamma delta iT platform, are the first two programs. Bristol Myers Squibb has the ability to designate two more program subject to certain restrictions set forth in the agreement with Century.
Furthermore, rising government and private-sector financial support and improved awareness about stem cells and related research, potential clinical uses, and increased clinical applications are likely to offer market opportunities during the projection period. However, In the coming years, the high development expenses and immune rejection concerns may limit the global allogeneic cell therapy manufacturing market.
The Allogeneic cell therapy manufacturing industry was led by North America in 2021. The primary driving factor for regional market expansion is rising interest in induced pluripotent stem cells (iPSCs) and rising demand for gene and cell therapies.
For more Customization in this Report, Connect with us at: https://www.insightaceanalytic.com/customisation/1194
The following key companies are engaged in the Allogeneic Cell Therapy Manufacturing market:
Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell, and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and Other Prominent Player among others.
Get Extra Discount on Allogeneic Cell Therapy Manufacturing Market Report, if your Company is Listed in Above Key Players List @ https://www.insightaceanalytic.com/enquiry-before-buying/1194
Tel.: +1 551 226 6109 Email: [email protected]
PR-Wirein, Financial Content, Extended Distribution, iCN Internal Distribution, Research Newswire, English